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Changing trends in the use of novel oral
anticoagulants and warfarin for treating
non-valvular atrial fibrillation
Alexander Birkinshaw1, Christopher H Fry2, David Fluck1,
Pankaj Sharma3 and Thang S Han3
Abstract
Background: Prevention of thromboembolism by novel oral anticoagulants is increasing, whilst use of vitamin K
antagonists is on the decline. We assessed changes in the use of these anticoagulants in treating non-valvular atrial
fibrillation between 2014 and 2018.
Methods: One-hundred and sixty-two consecutive patients (95 men, 67 women) with non-valvular atrial fibrillation,
mean age 72.3 years (standard deviation¼ 11.0), underwent cardiac assessment in a single cardiac unit. Use of anti-
coagulants at the time of investigation was documented: overall 83 (51.2%) patients were prescribed novel oral anti-
coagulants and 79 (48.8%) warfarin treatment. Trends in treatment rates with either anticoagulant class over time were
characterised by calculating the average annual percentage change using a Joinpoint Regression Program 4.7.0.0.
Results: There were diverging trends in anticoagulant treatment from 2014 to 2018 without join points: yearly increase
in novel oral anticoagulant treatment (41.9, 45.5, 53.7, 53.1 and 72.7%, average annual percentage change¼ 16.2%, 95%
confidence interval¼ 5.8% to 27.5%, p< 0.001), and decrease in warfarin treatment (57.1, 54.5, 46.3, 46.9 and 27.3%,
average annual percentage change¼14.4%, 95% confidence interval¼25.2% to 2.1%, p< 0.001).
Conclusions: Changing trends in treatment with anticoagulants for patients with non-valvular atrial fibrillation
observed within less than two years provide important information to healthcare services to estimate future
pharmaco-economic costs for such treatments.
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Introduction
Atrial fibrillation (AF), the most common sustained
cardiac arrhythmia, is associated with excess cardiovas-
cular morbidity and mortality.1–3 The prevalence of AF
rises with advancing age, from about 0.5–1% at age
50–59 years to 10–15% at age 80 years and over.4,5 It
is estimated that there will be up to 12 million people in
the US and 18 million people in Europe living with AF
in 40 to 50 years from now.6–8
Since their introduction in the UK and the rest of
Europe in 2008,9 novel oral anticoagulants (NOACs)
are increasingly being used to prevent thromboembo-
lism in a number of conditions such as AF, myocardial
infarction, ischaemic stroke and pulmonary embo-
lism.10,11 Consequently, the use of vitamin K
antagonists (VKAs), primarily warfarin, has declined
progressively.12,13 The decision to select NOACs as
treatment of choice for non-valvular atrial fibrillation
(NVAF) has been supported by a number of clinical
1Department of Cardiology, Ashford & St Peter’s Foundation Trust,
Chertsey, UK
2School of Physiology, Pharmacology and Neuroscience, University of
Bristol, Bristol, UK
3Institute of Cardiovascular Research, Royal Holloway, University of
London, Egham, UK
Corresponding author:
Thang S Han, FRCP, Institute of Cardiovascular Research, Royal









Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-
NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and dis-
tribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.
sagepub.com/en-us/nam/open-access-at-sage).
trials favouring their effectiveness and safety of
NOACs over Warfarin.14 Guidelines for management
of NVAF with NOACs have been published by the
European Heart Rhythm Association (EHRA) since
201315 with continual update (www.NOACfor AF.
eu), and also influence the use of NOACs. It is impor-
tant to continue to monitor the use of these anticoagu-
lants in order to provide evidence-based information to
healthcare services for resource requirements. In this
study, we aimed to assess the changing trends in the




We studied 162 patients (95 men, 67 women) with
NVAF, mean age 72.3yrs (SD¼ 11.0, range 37.4–
89.2), who underwent cardiac assessment in a single
Cardiac Unit. Patients were referred by physicians
and surgeons from acute admissions and outpatient
clinics. There was a variety of reasons for referral
including symptoms of chest pain and shortness of
breath, newly diagnosed AF, paroxysmal AF with
recurrent transient ischaemic attacks, and abdominal
aortic aneurysm repairs. The use of anticoagulants at
the time of their original investigation for each year
between 2014 and 2018 was documented: 83 patients
were treated with NOACs and 79 with warfarin. None
of the patients had a history of major bleeding.
Statistical analysis
Trends in treatment rates with either anticoagulant
class over time were examined using the Joinpoint
Regression Program 4.7.0.0 (surveillance.cancer.gov/
joinpoint/). This technique allows detection of join
points in data sets and calculates the annual percentage
change (APC) for individual linear segments (i.e. dif-
ferent slopes) if one or more join points exist, as well as
average annual percentage change (AAPC) for the
entire period of study. If no join points exist then
APC is the same as AAPC. Results are expressed as
percentage (%) change either each year or over the
whole period, the latter includes the 95% confidence
interval (CI).
Results
A total of 83 patients were on NOAC treatment with
mean age of 71 years (SD 12) and similar sex distribu-
tion. There were 14 patients (16.9%) aged 85 years or
older. Rivaroxaban was the most popular choice of
NOAC treatment (54%) (Table 1).
There were diverging trends in anticoagulant treat-
ment from 2014: with year-on-year increase in NOAC
use (42.9, 45.5, 53.7, 53.1 and 72.7%) and a decrease in
warfarin treatment (57.1, 54.5, 46.3, 46.9 and 27.3%)
(Figure 1). By 2016, the use of NOACs had surpassed
that of warfarin and continued to rise into 2018.
Joinpoint regression analysis did not detect any join
points for either NOACs (slope¼ 0.150) or warfarin
(slope¼0.156) indicating a single curvilinear rela-
tionship between the use of anticoagulants and period
of study was adequate (Figure 2). Trends in treatment
rates over time increased progressively for NOACs:
AAPC of 16.2% (95% CI¼ 5.8–27.5%, p< 0.001)
(Figure 2(a)), and decline for Warfarin: AAPC of
14.4% (95% CI¼25.2% to 2.1%, p< 0.001)
(Figure 2(b)).
Except for the first year of study (2014) when there
was none of these older individuals being treated with
Figure 1. Proportions of patients with NVAF treated with
NOACs (black bars) or with warfarin (white bars) between
2014 and 2018.
Table 1. Demographic characteristics and numbers of patients
with non-valvular atrial fibrillation (NVAF) treated with different







Men: women 43: 40 51.8: 48.2






aThe numbers are small therefore further verification is needed.
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an NOAC, the proportions of older patients (85) on
NOAC treatment within each year were 10%, 7% and
6% in 2015, 2016 and 2017 respectively, but rose to
25% in 2018 (Figure 3).
Discussion
This study shows that NOACs are now the anticoagu-
lant of choice for NVAF treatment. Our study is con-
sistent with a number of reports on the use of these
agents over recent years for treatment of AF, myocar-
dial infarct and cerebral ischaemic episodes.10,12,16,17
This information provides important information to
healthcare services when planning resource distribu-
tions owing to the rising trends in prevalence and inci-
dence of AF.18,19
These changes are due to a number of advantages of
NOACs over VKAs: NOACS are more effective in pre-
vention of ischaemic disease while less likely to associ-
ate with intracranial bleeding, and no worse in gastric
bleeding.11,20 The elimination of regular blood test
monitoring (international normal ratio (INR) for war-
farin) is beneficial both to patients and healthcare sys-
tems. In addition, NOACs such as Rivaroxaban can be
reversed almost immediately using prothrombin com-
plex concentrates21 while the anticoagulant effect of
dabigatran has been shown to be completely reversed
by the specific antidote Idarucizumab (a humanised
monoclonal antibody fragment)22 which is important
in emergency situations such as haemorrhage or sur-
gery. However, warfarin remains an essential drug, as
NOAC treatment is not suitable for all patients, includ-
ing those who have an allergy to these agents, potential
interactions with other drugs, or those with kidney
impairment14 or valvular AF.23 Given the ever increas-
ing numbers of people living with AF, projected to 1.8
million in the UK alone24 and up to 30 million in
Europe and US by 2060,6–8 INR monitoring for
those who require warfarin treatment will continue to
incur a substantial cost to healthcare resources.
Our observations of the curvilinear relationship
between NOAC treatment and years of study may be
explained by the publication of the European Society
Cardiology guidelines in 201625 and EHRA position
statement on NOAC treatment of AF in 2018.15
These guidelines also encourage the use of NOACs in
older patients, which coincide with the sudden rise in
the proportions of older individuals (85 years) on
NOAC treatment seen in our study.
This study is limited by its relatively small number of
patients; therefore, the association of the changing pro-
portions of patients treated with anticoagulants each
year of study may not be the same as the trends
observed in this study. This will lead to some uncer-
tainty in the estimation of future uses of these different
drug classes, or when their use attains a new steady
state. This relationship may also be influenced by the
endorsement from published guidelines (see above). In
addition it should be stressed that this study was
restricted to NVAF patients. Our study focussed on
Figure 2. Trends in NVAF treatment with NOACs (a) or with
warfarin (b) between 2014 and 2018.
Figure 3. Proportions of older patients (85 years) on NOAC
treatment in within each year of study between 2014 and 2018.
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the prevalence of treatment at the time when patients
were undergoing cardiac assessment, rather than new
cases. It is possible that bias was introduced since some
patients might already have switched from one type of
anticoagulant to another,26 or discontinued treatment,
to suit their treatment tolerability.27 The increasing
trend in NOAC treatment and declining trend in war-
farin treatment therefore represents net year-on-year
prevalence. An alternative method would be to com-
pare unselected consecutive patients in each year and
record new patients being prescribed each class of anti-
coagulant, but would require a different (prospective)
study design. We did not collect data on the history of
stroke but this would be expected to be high. Our
recent study of 2643 patients admitted with an acute
ischaemic stroke showed that there were 666 patients
(20.1%) with a history of AF and 171 patients (6.5%)
with newly diagnosed AF.17
In conclusion, changing trends in treatment with
anticoagulants of NVAF observed in the present
study provide important information to healthcare
services for evaluating future pharmacological health-
care costs.
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